ICU Medical (NASDAQ: ICUI) reported Q2 EPS of $1.88, $0.24 better than the analyst estimate of $1.64. Revenue for the quarter came in at $321.7 million versus the consensus estimate of $305.43 million.

Fiscal Year 2021 Guidance Update:

The Company is updating its full year 2021 guidance of adjusted EBITDA from a range of $245 million to $265 million to a range of $250 million to $260 million and adjusted diluted earnings per share from a range of $6.50 to $7.20 to a range of $6.80 to $7.20

(*Consensus sees FY EPS of $6.93)

For earnings history and earnings-related data on ICU Medical (ICUI) click here.